SHYNDEC(SH:600420)2020-04-24 16:00Financial Performance - Operating revenue for the period was ¥3,303,053,252.67, reflecting a growth of 4.05% year-on-year[10] - Net profit attributable to shareholders was ¥135,423,833.58, a decrease of 26.86% compared to the same period last year[10] - Basic earnings per share decreased by 24.76% to ¥0.1319 from ¥0.1753 in the previous year[10] - The weighted average return on equity fell by 0.91 percentage points to 1.77%[10] - The company expects significant changes in cumulative net profit compared to the previous year, but specific forecasts were not provided[22] - The total profit for Q1 2020 was ¥54,789,504.38, down 67.6% from ¥169,186,906.85 in Q1 2019[48] - Net profit for Q1 2020 was ¥183,256,375.41, a decrease from ¥261,435,748.36 in Q1 2019, reflecting a decline of approximately 30%[44] - The net profit for Q1 2020 was ¥45,528,294.38, a decrease of 72% from ¥162,687,657.71 in Q1 2019[49] Cash Flow - Net cash flow from operating activities was negative at ¥336,707,670.92, a decline of 235.73% year-on-year[10] - The net cash flow from operating activities decreased to -¥336,707,670.92, a 235.73% decline, as cash received from sales fell significantly[19] - The cash flow from operating activities for Q1 2020 was negative at -¥336,707,670.92, compared to a positive cash flow of ¥248,072,812.28 in Q1 2019[54] - The company experienced a decrease in cash flow from operating activities, totaling ¥2,601,394,628.00 in Q1 2020, down from ¥2,697,332,761.30 in Q1 2019[54] - The net cash flow from investment activities was CNY -392,140,820.19, worsening from CNY -286,164,051.22 in the previous year[61] - The net cash flow from financing activities improved to -¥464,137,619.48, a 31.46% increase, driven by new epidemic prevention loans[19] Assets and Liabilities - Total assets at the end of the reporting period reached ¥18,436,839,246.57, an increase of 4.53% compared to the end of the previous year[10] - Accounts receivable increased to ¥2,542,820,697.61, a 136.40% increase compared to the previous year due to increased revenue in the raw material drug segment and longer collection periods[16] - Short-term borrowings increased to ¥2,597,242,218.64, a 42.24% rise, primarily from new epidemic prevention loans and working capital loans[16] - Total liabilities increased from $8.44 billion to $9.05 billion, reflecting a growth of about 7.2%[30] - Total current liabilities rose from $6.49 billion to $7.20 billion, an increase of approximately 10.7%[30] - The total liabilities amounted to CNY 8,435,269,701.51 as of January 1, 2020[67] Shareholder Information - The total number of shareholders at the end of the reporting period was 35,891[13] - The top three shareholders held a combined 56.54% of the shares, with Shanghai Pharmaceutical Industry Research Institute holding 23.32%[13] - Shareholders' equity attributable to the parent company increased from $7.59 billion to $7.72 billion, a growth of approximately 1.8%[30] Other Financial Metrics - Government subsidies recognized in the current period amounted to ¥8,433,346.63[12] - The company reported a total of ¥6,076,664.18 in non-recurring gains and losses for the period[12] - Research and development expenses rose significantly to ¥10,275,864.92 in Q1 2020, compared to ¥1,343,789.79 in Q1 2019, marking an increase of 664%[48] - The company experienced a credit impairment loss of ¥50,789,464.85 in Q1 2020, compared to ¥24,070,105.24 in Q1 2019, indicating an increase in credit risk[44]